Humacyte Initiates Phase 2a Trial of Bioengineered Vessel for Coronary Bypass Surgery

• Humacyte initiated a first-in-human Phase 2a trial of its bioengineered coronary vessel for bypass surgery; enrollment is open.
• The study will assess safety and efficacy in 10 adults, checking vessel patency at two months with follow-up through three years.
• Trial design and preclinical results were presented at American Heart Association Scientific Sessions in Chicago on Nov. 7-8, 2026.
• Animal studies showed bypass vessels remained open and became populated with host cells, supporting development of an off-the-shelf alternative to harvested vessels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872592) on November 09, 2026, and is solely responsible for the information contained therein.